26/02/2025 Study

The chart shows the growth of an initial investment of €10,000 in 26/02/2025 Study, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Jul 25, 2019, 26/02/2025 Study's average daily return is +0.06%, while the average monthly return is +1.27%. At this rate, an investment would double in approximately 4.6 years.

Historically, 63% of months were positive and 37% were negative. The best month was Apr 2026 with a return of +9.7%, while the worst month was Mar 2020 at -7.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.

On a daily basis, 26/02/2025 Study closed higher 57% of trading days. The best single day was Mar 24, 2020 with a return of +7.8%, while the worst single day was Mar 12, 2020 at -7.8%.

26/02/2025 Study has an annualized alpha of 8.41%, beta of 0.44, and R2 of 0.34 versus S&P 500 Index. Calculated based on daily prices since July 25, 2019.

• This portfolio participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (85.91%) than losses (77.84%) - typical of diversified or defensive assets.
• Beta of 0.44 may look defensive, but with R2 of 0.34 this portfolio is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
• R2 of 0.34 means the benchmark explains less than half of this portfolio's behavior - treat beta with caution or consider switching to a more representative benchmark.

26/02/2025 Study has an expense ratio of 0.22%, which is considered low. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

26/02/2025 Study ranks 81 for risk / return — in the top 81% of Portfolios on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

The current 26/02/2025 Study Sharpe ratio is 2.39 as of Jun 13, 2026 (the value is recalculated daily), calculated over the past 12 months.

Compared to the broad market, where average Sharpe ratios range from 1.54 to 2.41, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of 26/02/2025 Study compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the 26/02/2025 Study. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 26/02/2025 Study was 28.65%, occurring on Mar 23, 2020. Recovery took 115 trading sessions.

The current 26/02/2025 Study drawdown is 2.19%.

The chart below shows the rolling one-month volatility.